Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2007

View Archived Issues

Positive results for Regeneron's proof-of-concept study of rilonacept for gout / News in Context

Novel CXCR2 antagonist useful in models of acute and chronic inflammation

GenVec signs CRADA for malaria vaccine development

ProMetic Life Sciences expands PBI-1402 program to include cancer-related anemia

Positive results for Renovo's phase II trial of Juvista for treatment of wounds and scars

New antipsychotic, antidepressive and anxiolytic agents cited in patent literature

CRT, UCL and Novozymes to codevelop novel anticancer therapeutics

FDA opens Corcept's IND for Corlux for Cushing's syndrome allowing initiation of phase III study

Estrogen-dependent breast cancer growth in vivo suppressed by KW-2581

New compounds for treatment of HCV infection revealed

Recent patents impart new therapeutic agents for cancer

FDA Advisory Committees reaffirm current dosing practices for ESAs

Inhibitex licenses HIV integrase and hepatitis C polymerase inhibitors from UGARF

Phenomix begins phase IIb trial of PHX-1149 for type 2 diabetes

Phosphagenics to initiate phase II trials of TMP/Insulin for diabetes

BioSante and FDA reach agreement on LibiGel development requirements

Update on Aspreva and Roche's development of CellCept for lupus nephritis

Nventa begins phase I trial of HspE7 dosed with an adjuvant for CIN

Positive results for Chelsea's new formulation of CH-1504 for RA

Trubion reports preliminary analysis of phase IIb trial of TRU-015 for RA

New drug targets in neuropathic pain described

Minocycline shows neuroprotection in animal models of Alzheimer's disease

Pivotal phase III prophylactic HAE trial of Cinryze meets primary endpoint

FDA grants Metabasis' MB-07133 orphan drug designation for HCC

Novartis launches daptomycin for MSSA and MRSA bloodstream and heart infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...